Keith Argenbright
Overview
Explore the profile of Keith Argenbright including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
290
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Joseph A, Walker A, Irek M, Berry E, Argenbright K, Jacobe H
J Cosmet Dermatol
. 2022 May;
21(11):6449-6452.
PMID: 35531786
No abstract available.
2.
Prasad S, Black S, Chen H, Joseph A, Latour E, Berry E, et al.
J Am Acad Dermatol
. 2022 Jan;
87(5):1102-1104.
PMID: 35077778
No abstract available.
3.
Argenbright K, Berry E
J Natl Cancer Inst Monogr
. 2021 Sep;
2021(57):31-34.
PMID: 34478508
In 2006, the Institute of Medicine recognized that cancer survivors faced complex physical and emotional health problems, often overlooked or inadequately managed. In Texas, access to programs specifically designed to...
4.
Bayers S, Orseth M, Prasad S, Hynan L, Berry E, Argenbright K, et al.
J Am Acad Dermatol
. 2021 Apr;
86(5):1111-1112.
PMID: 33795146
No abstract available.
5.
Gupta S, Coronado G, Argenbright K, Brenner A, Castaneda S, Dominitz J, et al.
CA Cancer J Clin
. 2020 Jun;
70(4):283-298.
PMID: 32583884
Uptake of colorectal cancer screening remains suboptimal. Mailed fecal immunochemical testing (FIT) offers promise for increasing screening rates, but optimal strategies for implementation have not been well synthesized. In June...
6.
Berry E, Miller S, Koch M, Balasubramanian B, Argenbright K, Gupta S
Clin Gastroenterol Hepatol
. 2019 May;
18(3):647-653.
PMID: 31085338
Background & Aims: Noninvasive tests used in colorectal cancer screening, such as the fecal immunochemical test (FIT), are more acceptable but detect neoplasias with lower levels of sensitivity than colonoscopy....
7.
Gupta S, Miller S, Koch M, Berry E, Anderson P, Pruitt S, et al.
Am J Gastroenterol
. 2016 Aug;
111(11):1630-1636.
PMID: 27481306
Objectives: Offering financial incentives to promote or "nudge" participation in cancer screening programs, particularly among vulnerable populations who traditionally have lower rates of screening, has been suggested as a strategy...
8.
Gupta S, Halm E, Rockey D, Hammons M, Koch M, Carter E, et al.
JAMA Intern Med
. 2013 Aug;
173(18):1725-32.
PMID: 23921906
Importance: Colorectal cancer (CRC) screening saves lives, but participation rates are low among underserved populations. Knowledge on effective approaches for screening the underserved, including best test type to offer, is...
9.
Gupta S, Tong L, Anderson P, Rose B, Carter E, Koch M, et al.
Am J Med Sci
. 2012 Jul;
345(2):99-103.
PMID: 22814361
Background: Optimizing colorectal cancer (CRC) screening requires identification of unscreened individuals and tracking screening trends. A recent National Institutes of Health State of the Science Conference, "Enhancing Use and Quality...
10.
Sairamesh J, Rajagopal R, Nemana R, Argenbright K
AMIA Annu Symp Proc
. 2010 Mar;
2009:553-7.
PMID: 20351916
In this paper we present risk-estimation models and methods for early detection of patient non-adherence based on unstructured text in patient records. The primary objectives are to perform early interventions...